Efficacy and safety of teclistamab followed by autologous stem cells transplant in functional high-risk and triple class refractory multiple myeloma. (2025). Mediterranean Journal of Hematology and Infectious Diseases, 17(1), e2025051. https://doi.org/10.4084/MJHID.2025.051